Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Kite, A Gilead Company.

Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic Malignancies


Release Date: June 29, 2018
Expiration Date: June 29, 2019
Media: Internet - based
 

Activity Overview

PER Global®, LLC, the global affiliate of Physicians’ Education Resource®, LLC, (PER®) is pleased to present the CME-certified online activity titled Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic Malignancies. This innovative activity is an archived version of the live-streamed interactive webcast held on May 24, 2018, and led by international hematologic malignancies experts Paolo Ghia, MD, PhD, Krishna V. Komanduri, MD, and Jae H. Park, MD.  Our experts will bring you key insights into the clinical application of chimeric antigen receptor T-cell (CAR-T) therapy.  For patients with leukemia or lymphoma, stem cell transplantation (SCT) provides the best chance for long-term remission; however, not all patients are eligible, and patients who relapse after SCT have a poor prognosis. This has led to the development of therapies with nonoverlapping mechanisms of action, such as CAR T cells.
 
This exciting online activity offers education to augment your foundation of knowledge and clinical competence in several areas, including:
  • The unique mechanism of action of CAR T cells
  • Clinical considerations for the use of CAR T cells, and differentiation from chemotherapy and targeted therapy
  • Data demonstrating durable complete responses in patients with heavily pretreated B-cell acute lymphoblastic leukemia or aggressive B-cell lymphoma
  • Managing adverse events associated with CAR T cells 
Join us online for Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic Malignancies, which will bring medical conference‒caliber education to the convenience of your screen!

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Kite, A Gilead Company.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.


Target Audience

This educational activity is directed towards ex-US clinicians, including medical oncologists, hematologists, nurses, and fellows who treat patients with hematologic malignancies. Physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies are also invited to participate.

Learning Objectives

Upon completion of this activity, you should be better prepared to:

  • Explain the mechanism of action of CAR T cells in hematologic malignancies, and differentiate between available and emerging therapies
  • Describe the manufacture of CAR T cells and the standards under which manufacturing is conducted
  • Discuss recent clinical trial data concerning the application of CAR T-cell strategies in the context of evolving treatment paradigms for hematologic malignancy management
  • Delineate appropriate techniques to identify and manage different treatment-related toxicities in the care of patients who receive CAR T-cell therapies
Moderator
Paolo Ghia
Paolo Ghia, MD, PhD
Università Vita-Salute San Raffaele
Director, Strategic Research Program on CLL
IRCCS San Raffaele Scientific Institute
Milan, Italy

DisclosuresGrant/Research Support: AbbVie, Janssen, Gilead; Consultant: AbbVie, Acerta, BeiGene, Janssen, Pharmacyclics, Gilead; Speakers’ Bureau: Gilead

Faculty
Krishna V. Komanduri
Krishna V. Komanduri, MD
Kalish Family Chair in Stem Cell Transplantation
Professor of Medicine, Microbiology & Immunology
Director, Adult Stem Cell Transplant Program
Sylvester Comprehensive Cancer Center
University of Miami
Miami, FL

DisclosuresAd Hoc Advisor: Kite, Novartis, Juno; Co-Investigator: Kite, Novartis, Adaptimmune, Juno

Jae H. Park
Jae H. Park, MD
Assistant Attending Physician
Department of Medicine, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY

DisclosuresConsultant: Amgen, Novartis, Adaptive Biotechnologies

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that creates a conflict of interest (COI).

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing education purposes only, and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of PER® or the company that provided commercial support for this activity.

 

PER Pulse™ Recaps

1 of 3

Introduction and Considerations for Use of CAR T Cells

Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic Malignancies highlighted key clinical data with chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies. The program chair, Paolo Ghia, MD, PhD, along with expert faculty, Krishna V. Komanduri, MD, and Jae H. Park, MD, discussed developments with CAR T cells in patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.

This first of 3 PER® Pulse™ Recaps from this Year in Review™ focuses on unique characteristics of CAR T cells and considerations for incorporation of this therapeutic modality.

  • CAR T cells are genetically modified T cells that are designed to recognize specific antigens on tumor cells, resulting in the activation and proliferation of the CAR T cells, and eventually resulting in significant and durable destruction of malignant cells.
  • CAR T cells currently must be manufactured for each patient, in contrast to other modalities that can be mass-produced and available immediately. Currently, the manufacture of CAR T cells takes 2 to 3 weeks, and patients may require supplemental bridging therapy while waiting for reinfusion.
  • Therefore, the process for preparing a candidate patient for CAR T-cell therapy should begin far in advance of the currently indicated failure of ≥2 lines of therapy.

2 of 3

Application of CAR T Cells in ALL

Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic Malignancies highlighted key clinical data with chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies. The program chair, Paolo Ghia, MD, PhD, along with expert faculty, Krishna V. Komanduri, MD, and Jae H. Park, MD, discussed developments with CAR T cells in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma.

This second of 3 PER® Pulse™ Recaps from this Year in Review™ focuses on the development of CAR T cells in patients with relapsed/refractory ALL.

  • In August 2017, tisagenlecleucel was the first CAR T-cell therapy to receive approval from the US Food and Drug Administration, with an indication in patients aged ≤25 years with B-cell precursor ALL in second relapse or later.
  • This approval was based on the phase II ELIANA trial, which enrolled 75 patients aged 3 to 21 years with B-cell ALL.
  • Initial results in the ELIANA trial showed an overall response rate (ORR) of 81%, with a complete response (CR) rate of 60%. Updated results within an additional year of follow-up demonstrated an ORR of 82%, with 62% of patients being relapse-free at 24 months. The rates of grade 3/4 cytokine release syndrome (CRS) and neurotoxicity were 49% and 13%, respectively, and similar to the original report.

3 of 3

Application of CAR T Cells in NHL

Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic Malignancies highlighted key clinical data with chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies. The program chair, Paolo Ghia, MD, PhD, along with expert faculty, Krishna V. Komanduri, MD, and Jae H. Park, MD, discussed developments with CAR T cells in patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma (NHL).

This third of 3 PER® Pulse™ Recaps from this Year in Review™ focuses on the development of CAR T cells in patients with relapsed/refractory NHL.

  • In October 2017, axicabtagene ciloleucel (axi-cel) became the first CAR T-cell therapy to be approved by the US Food and Drug Administration for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, or DLBCL arising from follicular lymphoma, who progress after ≥2 lines of therapy.
  • This approval was based on data from the phase II ZUMA-1 trial. Initial results showed an ORR of 82%, including a CR in 54%; an updated analysis with a median of 27.1 months’ follow-up showed an ongoing CR rate of 37%. The incidence of grade ≥3 CRS or neurotoxicity was 11% and 32%, respectively.
  • In May 2018 tisagenlecleucel was approved by the US FDA for patients who have received ≥2 prior lines of therapy for DLBCL NOS, high-grade B-cell lymphoma, or DLBCL arising from follicular lymphoma, based on the phase II JULIET trial. Updated results with a median of 19 months’ follow-up showed an ORR of 54%, including a CR rate of 40%. The incidence of grade 3/4 CRS and neurotoxicity was 23% and 11%, respectively.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
30
Filter By